Health Catalyst (NASDAQ: HCAT) reported second-quarter 2026 revenue of $70.5 million, exceeding the high end of its guided range of $68 million to $70 million. The healthcare technology firm also closed the divestiture of its Vitalware unit, using proceeds to fully retire approximately $160 million in credit facility debt.

The company delivered adjusted EBITDA of $9.9 million for the quarter, landing at the high end of the $9 million to $10 million guidance range. Management emphasized that the transaction eliminates roughly $19 million in annual GAAP interest expense and removes restrictive debt covenants, allowing the firm to focus on core technology investments under its Project Nexus transformation plan.

Financial Performance

Total revenue for Q2 2026 was driven by technology revenue of $48.8 million and professional services revenue of $21.7 million. Adjusted gross margin expanded to 51% from 50% in the prior-year period. Within this, adjusted technology gross margin stood at 63%, down from 66% year-ago, while adjusted professional services gross margin rose to 22% from 18%.

Adjusted operating expenses decreased to $25.9 million, or 37% of revenue, compared to $30.6 million (38% of revenue) in the prior-year period. Adjusted net income per share was $0.04 based on a weighted average share count of 74 million.

Balance Sheet and Divestiture

Health Catalyst divested Vitalware to MedMetrix for $147 million in total cash consideration, yielding net proceeds of $145.5 million after transaction costs. The company used these proceeds along with cash on hand to repay approximately $160 million in credit facility debt, including accrued interest and prepayment premiums.

Pro forma for the transaction, the company ended the quarter with approximately $82 million in cash, cash equivalents, and short-term investments, and zero debt. The deal eliminates an estimated $16.5 million in annual cash interest payments. A transition services agreement with MedMetrix will provide modest income offset for up to six months.

What the Numbers Show

The removal of Vitalware significantly alters the revenue composition and margin profile. While Vitalware was a higher-margin business contributing $11.4 million in first-half adjusted EBITDA, its exit reduces the full-year adjusted gross margin expectation to below 50%. This divergence highlights the trade-off between immediate balance sheet strengthening—eliminating $19 million in annual interest costs—and near-term margin pressure as the company shifts focus to lower-margin migration efforts and core technology builds.

Guidance Update

Reflecting the loss of five months of Vitalware revenue and continued investments in AI and platform migrations, Health Catalyst updated its full-year 2026 outlook:

• Total revenue expected between $246 million and $249 million
• Adjusted EBITDA projected at $18 million to $18.5 million

For the third quarter, the company expects total revenue of $55 million to $56 million and adjusted EBITDA of breakeven to $500,000. Management noted that migration-related churn headwinds are expected to persist through the end of 2027, with annualized services revenue anticipated to settle closer to $55 million.

Health Catalyst Inc (NASDAQ: HCAT) granted 2,747,385 restricted stock units to Simeon Kohl as an inducement for his appointment as Chief Executive Officer and President.

The Compensation Committee of the Board of Directors approved the awards on September 14, 2026, under the company’s 2026 Employment Inducement Incentive Plan. The grant aligns with Nasdaq Listing Rule 5635(c)(4), which permits equity awards to non-employees as material inducements for employment.

Vesting Schedule

The RSUs vest subject to Mr. Kohl’s continued employment:

• 915,975 RSUs vest on September 14, 2027.
• The remaining units vest in eight approximately equal quarterly installments thereafter.

Open Market Purchases

Mr. Kohl acquired an aggregate of 59,000 shares of Health Catalyst common stock through open market purchases on September 11, 2026, and September 14, 2026. The weighted average purchase price was $1.787188 per share.

What the Numbers Show

The immediate ownership stake established by Mr. Kohl through open market purchases represents a modest capital commitment relative to the size of the equity inducement. The 59,000 shares purchased at roughly $1.79 per share contrast with the 2.75 million RSUs granted, highlighting a compensation structure heavily weighted toward long-term retention via vesting schedules rather than upfront cash-equivalent stock acquisition.